Cancer Therapy: Preclinical

ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation

Laura Biddlestone-Thorpe1, Muhammad Sajjad1, Elizabeth Rosenberg1, Jason M. Beckta1,2, Nicholas C.K. Valerie1, Mary Tokarz1, Bret R. Adams1, Alison F. Wagner1, Ashraf Khalil1, Donna Gilfor1, Sarah E. Golding1, Sumitra Deb2,4, David G. Tenesie3, Alan Lau3, Mark J. O’Connor3, Kevin S. Choe6, Luis F. Paraddi6, Sang Kyun Lim6, Nital D. Mukhopadhyay3,4, and Kristoffer Valerie1,2,4

Abstract

Purpose: Glioblastoma multiforme (GBM) is the most lethal form of brain cancer with a median survival of only 12 to 15 months. Current standard treatment consists of surgery followed by chemoradiation. The poor survival of patients with GBM is due to aggressive tumor invasiveness, an inability to remove all tumor tissue, and an innate tumor chemoresistance and radioresistance. Ataxia–telangiectasia mutated (ATM) is an excellent target for radiosensitizing GBM because of its critical role in regulating the DNA damage response and p53, among other cellular processes. As a first step toward this goal, we recently showed that the novel ATM kinase inhibitor KU-60019 reduced migration, invasion, and growth, and potently radiosensitized human glioma cells in vitro.

Experimental Design: Using orthotopic xenograft models of GBM, we now show that KU-60019 is also an effective radiosensitizer in vivo. Human glioma cells expressing reporter genes for monitoring tumor growth and dispersal were grown intracranially, and KU-60019 was administered intratumorally by convection-enhanced delivery or osmotic pump.

Results: Our results show that the combined effect of KU-60019 and radiation significantly increased survival of mice 2- to 3-fold over controls. Importantly, we show that glioma with mutant p53 is much more sensitive to KU-60019 radiosensitization than genetically matched wild-type glioma.

Conclusions: Taken together, our results suggest that an ATM kinase inhibitor may be an effective radiosensitizer and adjuvant therapy for patients with mutant p53 brain cancers. Clin Cancer Res; 19(12); 3189–200. ©2013 AACR.

Introduction

Each year in the United States about 7 of 100,000 people are diagnosed with high-grade glioma, classified by the World Health Organization (WHO) as grade 3 and 4 gliomas. Grade 4 is also referred to as glioblastoma multiforme (GBM). Hallmark characteristics of GBM include uncontrolled cell proliferation, diffuse infiltration, and resistance to apoptosis (1, 2). These characteristics, at least in part, account for GBM’s poor prognosis and resistance toward radio- and chemotherapy, and a median survival of just 12 to 15 months (3). Primary GBM (type II) arises de novo with no prior symptoms or evidence of lower grade tumor and occurs most frequently in individual 60 years or older. Secondary GBM (type I) occurs in younger patients from lower grade brain tumors. Type II constitutes the majority (>90%) of all GBMs, whereas the remaining are type I. It has been suggested that genetic mutations and amplifications affecting signaling pathways may account, in part, for GBM’s aggressive nature (4, 5). GBMs are also classified into 4 different subgroups based on gene expression profiling: (i) classical, (ii) mesenchymal, (iii) neural, and (iv) proneural (6, 7). Type II GBM is mostly found in the classical subgroup with EGFR receptor (EGFR) amplifications and PTEN deletions, as well as some with mutations in p53 (8, 9). On the other hand, type I is usually found in the proneural subgroup with frequent mutations in platelet-derived growth factor receptor (PDGFR), IDH1, and p53 (6). The frequency of p53 mutations in type I GBM is 65% or greater, whereas classical GBM harbors p53 mutations 30% of the time (10).

Mutation of the ataxia–telangiectasia (A–T) mutated (ATM) gene is the underlying cause of the rare autosomal...
**Translational Relevance**

KU-60019 is a novel, second-generation, and highly specific ataxia–telangiectasia mutated (ATM) kinase inhibitor that blocks radiation-induced DNA damage response and potently radiosensitizes human glioma cells in vitro. In addition, KU-60019 alone inhibits glioma cell migration, invasion, and growth, suggesting that critical growth and prosurvival signaling pathways are also under control of ATM. To see whether KU-60019 would be an effective radiosensitizer in vivo, we used orthotopic human glioma xenograft models varying in p53 status and invasiveness. Our results show, for the first time, that an ATM inhibitor, KU-60019, and radiation significantly increase survival of mice 2- to 3-fold over controls. Importantly, we show that glioma with mutant p53 is much more sensitive to KU-60019 radiosensitization than genetically matched wild-type glioma. In conclusion, our results suggest that an ATM kinase inhibitor may be an effective radiosensitizer and adjuvant therapy for patients with mutant p53 brain cancers.

We show herein that orthotopic gliomas are radiosensitized with the ATM kinase-specific inhibitor, KU-60019, resulting in significant increases in the survival of mice. Importantly, p53-mutant glioma is much more sensitive to the combination of KU-60019 and radiation resulting in impressive extended survival, and in some cases, the apparent curing of treated mice.

**Materials and Methods**

**Reagents**

Antibodies used in both Western blotting and/or immunohistochemistry were anti-p-(S1981)-ATM (Millipore); anti-ATM (GeneTex); anti-Ki67 (Novus Biologicals); 53BP1 (BD Biosciences); p53 (Cell Signaling Technology); glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Millipore); mouse anti-γ-H2AX (Millipore); anti-p-(S824)-KAP1 (Abcam); Alexa Fluor 594 goat anti-mouse immunoglobulin G (IgG), and Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen). Matrigel (BD Biosciences) was used for tumor implantation. KU-60019 was obtained from AstraZeneca.

**Cells, cell culture, and treatments**

Human glioblastoma U1242/luc-GFP cells have been described previously (20). U87/luc-DsRed and U87/luc-DsRed-p53(281G) cells were generated by infection of U87 cells with Fluc-DsRed2 lentivirus (22) followed by cell sorting, and subsequent infection with LNcx-p53 (281G) retrovirus and selection with G418. U1242/luc-GFP-p53 (281G) cells were generated the same way. Cell characterization included the ability to form intracranial tumors in athymic mice, and quantitative reverse transcriptase PCR expression profiling (U1242). Cells were not tested and authenticated by an external service provider. Pooled populations of cells were used in all instances. Irradiations were conducted using an MDS Nordion Gammacell 40 research irradiator with a Cs-137 source delivering at a dose rate of 1.05 Gy/min.

For the continuous KU-60019 exposure growth assay, cells were counted on a hemocytometer and seeded in a 12-well plate. After cells were allowed to grow for 48 hours, culture medium was removed, and medium containing KU-60019 (3 μmol/L) or dimethyl sulfoxide (DMSO) vehicle was added to triplicate wells and returned to the incubator. Seven days after initial exposure to drug, each well was trypsinized and counted on a Beckman Coulter counter, and total number of cells for each well was calculated. Counts from triplicate wells were averaged, and plotted.

Clonogenic radiosurvival experiments were carried out as described previously (18, 20, 21). Briefly, U87 and U1242 cells and derivatives were diluted, seeded on 10- or 6-cm dishes, and after the cells attached, treated with KU-60019 (3 μmol/L) or not in the medium for 1 hour before irradiation. Cells were incubated overnight, and the medium changed to nondrug containing medium 16 hours postirradiation. Cells were incubated for further 14 days, stained.
with crystal violet, and colonies consisting of 50 or more cells were counted by eye. Radiosensitization by KU-60019 was determined by fitting radiation survival curves using the linear quadratic equation, and dose enhancement ratios (DER) were determined by dividing the D_{37} dose of control cells by the D_{37} dose of treated cells. A DER more than 1 indicates radiosensitization.

Luciferase assay were conducted using a PerkinElmer Precisely (2103 Envision Multilabel plate reader) and luciferase kit from PerkinElmer and used as recommended by the manufacturer. For the radiosurvival assay, U87/luc-DsRed+/−p53-281G cells were serially diluted in 96-well microplates and irradiated with the indicated doses. Three days later, luciferase assay was conducted to determine viable cell numbers. The mouse glioma cells were derived from GBM of “Mut6” (hGFAP-Cre; p53 f/ f; NF1 f/ f; PTEN f/ f) mice (23). Tumors were harvested and enriched for stem-like cells by growing them as neurospheres in serum-free media supplemented with EGF and basic fibroblast growth factor (bFGF; ref. 24). Cells were plated in 96-well plates and treated with KU-60019 at the indicated concentrations and irradiated 3 hours later. After 6 days, cell viability was determined by CellTiter-Glo (Promega). Bioluminescence imaging (BLI) was conducted on a Caliper-IVIS-200 after subcutaneous injection of D-luciferin (Gold Biotechnology) at 30 mg/mL in PBS.

Flow cytometry
Flow cytometry was carried out as described previously (25). Cells were fixed in 100% methanol and permeabilized in 1% Triton X-100/casein. Cell-cycle distribution was analyzed by 7-amino-actinomycin D (7-AAD) and propidium iodide staining (5 mg/mL, 0.1% Triton X-100/PBS). Bromodeoxyuridine (BrdUrd) flow cytometry was carried out as recommended by the manufacturer (BD Biosciences) as described previously (26). Briefly, U87 and U87-281G cells were irradiated with 10 Gy or left untreated. After 16 hours, BrdUrd was added to the medium (10 μmol/L final), and 5 hours later cells isolated for further processing. Flow cytometry was conducted on a BD Biosciences FACS Canto flow cytometer at the Virginia Commonwealth University (VCU) Flow Cytometry Core Facility. Data were analyzed using the FACSDiva software.

Imaging and microscopy
Confocal fluorescence microscopy was conducted as previously described (25). Cells were grown on Lab-Tek glass slides coated with Matrigel. After treatment, cells were fixed with 3% paraformaldehyde, permeabilized with 0.5% Triton-X 100 in PBS, and blocked with casein/0.1% goat serum before exposure to primary antibodies followed by secondary antibodies Alexa 488 goat anti-rabbit or goat anti-mouse 546 Fab fragment (Invitrogen) at 1:500 dilution, and nuclei counterstained with 4′,6-diamidino-2-phenylindole.
Clinical Cancer Research

Biddlestone-Thorpe et al.

...Cells were imaged and analyzed using a Zeiss LSM 510 Meta imaging system in the VCU Microscopy Facility.

Following treatment with irradiation and KU-60019, animals were transcardially perfused with 3% paraformaldehyde followed by postfixing of brains and treatment with 30% sucrose until no longer buoyant. Brains were cut coronally through the injection site, and the hindbrain embedded in Tissue-Tek OCT Compound (Sakura), frozen on dry ice, and stored at −20°C. Cryosectioning was carried out on a Leica CM1850 cryostat with 6-μm thickness and slides were stored frozen until staining. Sections were rinsed in PBS, followed by pretreatment in sodium citrate antigen unmansing solution (0.01 mol/L sodium citrate; 0.05% Tween-20; pH 6.0) and boiled followed by aldehyde reduction with NaBH₄. Sections were permeabilized with 1% Triton-X-100/PBS and blocked with 10% normal goat serum in Triton-X-100/PBS before the exposure to primary antibodies followed by secondary antibodies [Alexa Fluor-594 goat anti-mouse IgG or Alexa Fluor-488 goat anti-rabbit IgG (Invitrogen)] and DAPI. Hematoxylin and eosin (H&E) staining was carried out on frozen sections fixed in 3% formaldehyde and stained with modified Mayer’s H&E Y. After dehydation with ethanol, sections were cleared with Histoclear (National Diagnostics #HS-200), and coverslips mounted on sections with Permount (Fisher #SPI15-100). Sections were imaged and analyzed using a Zeiss LSM 510 Meta imaging system at ×63 magnification in the Massey Cancer Center Flow Cytometry and Imaging Facility or using an Applied Imaging Ariol SL-50 system (Applied Imaging Corp.).

To ensure tumor take and equal tumor size distribution throughout the treatment groups, all mice injected with U1242/luc-GFP or U87/luc-DsRed cells were imaged using BLI typically at 5, 16, and 32 days postcell injection using a Caliper IVIS-200. If necessary, later images were also acquired. Fixed and unfixed brains were imaged on a Zeiss SV11 stereomicroscope (Zeiss) with a Hamamatsu digital CCD camera C4742-95-12RB (Hamamatsu) and AttoArc2/HB 100 Arc variable intensity microscopy illuminator system (Zeiss) using excitation/emission filters (GFP; 470/525, DsRed; 546/575), and a Caliper IVIS-200 system using GFP filters. Images were captured using AxioVision 3.1 or Living Image 4.0 software, and processed with Adobe Photoshop 5.0.

Animals and animal procedures

All procedures were carried out in accordance with protocol AM10197 approved by the VCU (Richmond, VA) Institutional Animal Care and Use Committee (IACUC).

All mice were subjected to a light/dark cycle of 12 hours with water and food available ad libitum. Athymic nude female mice (5–6-weeks old) were purchased from National Cancer Institute (NCI)-Frederick (Gaithersburg, MD). Mice weighing between 15 and 25 g were anesthetized intraperitoneally with a mixture of ketamine and xylazine (10 mg/kg; 1 mg/kg) in saline, and placed on a heating pad. A 1-cm sagittal incision was made, and the skull exposed. A 1-mm burr hole was made 2 mm left lateral and 1 mm posterior to the bregma. A small pocket was created in the brain by inserting a 26-gauge needle with a beveled edge to a depth of 3 mm. This location was found optimal for the insertion of the Brain Infusion Kit 3 (ALZET) cannula connected to an osmotic pump and was therefore used throughout these experiments. U1242/luc-GFP, U87/luc-DsRed, or derivatives thereof were trypsinized, washed, and resuspended in PBS and Matrigel (BD Biosciences), and loaded into a 5-mm thickness and slides were stored frozen until staining. Sections were rinsed in PBS, followed by pretreatment in sodium citrate antigen unmansing solution (0.01 mol/L sodium citrate; 0.05% Tween-20; pH 6.0) and boiled followed by aldehyde reduction with NaBH₄. Sections were permeabilized with 1% Triton-X-100/PBS and blocked with 10% normal goat serum in Triton-X-100/PBS before the exposure to primary antibodies followed by secondary antibodies [Alexa Fluor-594 goat anti-mouse IgG or Alexa Fluor-488 goat anti-rabbit IgG (Invitrogen)] and DAPI. Hematoxylin and eosin (H&E) staining was carried out on frozen sections fixed in 3% formaldehyde and stained with modified Mayer’s H&E Y. After dehydation with ethanol, sections were cleared with Histoclear (National Diagnostics #HS-200), and coverslips mounted on sections with Permount (Fisher #SPI15-100). Sections were imaged and analyzed using a Zeiss LSM 510 Meta imaging system at ×63 magnification in the Massey Cancer Center Flow Cytometry and Imaging Facility or using an Applied Imaging Ariol SL-50 system (Applied Imaging Corp.).

To ensure tumor take and equal tumor size distribution throughout the treatment groups, all mice injected with U1242/luc-GFP or U87/luc-DsRed cells were imaged using BLI typically at 5, 16, and 32 days postcell injection using a Caliper IVIS-200. If necessary, later images were also acquired. Fixed and unfixed brains were imaged on a Zeiss SV11 stereomicroscope (Zeiss) with a Hamamatsu digital CCD camera C4742-95-12RB (Hamamatsu) and AttoArc2/HB 100 Arc variable intensity microscopy illuminator system (Zeiss) using excitation/emission filters (GFP; 470/525, DsRed; 546/575), and a Caliper IVIS-200 system using GFP filters. Images were captured using AxioVision 3.1 or Living Image 4.0 software, and processed with Adobe Photoshop 5.0.

Animals and animal procedures

All procedures were carried out in accordance with protocol AM10197 approved by the VCU (Richmond, VA) Institutional Animal Care and Use Committee (IACUC).

All mice were subjected to a light/dark cycle of 12 hours with water and food available ad libitum. Athymic nude female mice (5–6-weeks old) were purchased from National Cancer Institute (NCI)-Frederick (Gaithersburg, MD). Mice weighing between 15 and 25 g were anesthetized intraperitoneally with a mixture of ketamine and xylazine (10 mg/kg; 1 mg/kg) in saline, and placed on a heating pad. A 1-cm sagittal incision was made, and the skull exposed. A 1-mm burr hole was made 2 mm left lateral and 1 mm posterior to...
ATM Inhibition Radiosensitizes p53-Mutant Glioma

Convection-enhanced delivery (CED) of KU-60019 was done on day 6, 9, and 12 postcell injection. A guide screw with a stylet (PlasticsOne, Inc.) was inserted into the burr hole to facilitate cell placement and subsequent drug infusions and the incision closed using vet-glue (GLUture Topical Tissue Adhesive; Abbott Laboratories). Next, a solution and the incision closed using vet-glue (GLUture Topical Tissue Adhesive; Abbott Laboratories). The skin was opened and the stylet removed before repeating the infusion followed by irradiation.

Statistical analysis

Mouse survival studies were modeled using Kaplan–Meier curves. Statistical analyses were conducted using log-rank test and mean survival in days was reported with SD for all treatment groups. Clonogenic radiosurvival experiments were analyzed by two-way ANOVA with radiation survival fraction as the response to cell type and radiation dose along with interaction. Least-squared means of the treatment difference were obtained from the model and tested with ANOVA F test. All statistical analyses were done in SAS v9.2.

Results

ATM kinase inhibitor KU-60019 radiosensitizes human glioma and mouse glioma stem cells

To confirm and validate the target for KU-60019 as the ATM kinase, U1242 and U87 cells were exposed to KU-60019 and radiation and extracts prepared for Western blotting with p-(S1981) ATM antibody. S1981 is a well-established radiation-induced auto-phosphorylation site (27). Both cell lines increased p-(S1981) ATM levels after exposure to radiation and KU-60019 suppressed this increase showing that ATM kinase was inhibited (Fig. 1A). Furthermore, U1242 and U87 cells were similarly radiosensitized in vitro in the presence of low levels of KU-60019 (Fig. 1B). U1242 cells show high DNA repair capacity (curved slope with low α/β ratio), whereas U87 cells have a straighter curve and thus lower repair capacity. Nevertheless, KU-60019 was able to radiosensitize both cell lines to a similar extent. When p53 null glioma cells isolated from a spontaneous mouse GBM model were grown as neurospheres and tested they were also found to be radiosensitized by KU-60019. Altogether, KU-60019 is an effective and specific radiosensitizer of established human glioma cells and primary mouse glioma stem cells in vitro in agreement with earlier studies (20, 21, 28, 29).

Human U1242/luc-GFP glioma cells form invasive tumors in mouse brain and show radiation dose-dependent increases in radiation-induced repair foci

One characteristic phenotype of human glioma is its invasiveness, which is rarely seen when human xenografts established from tissue culture cell lines are propagated as orthotopic tumors in mice. The U1242 human glioma cell line is unusual in that it has a stable, invasive, and very aggressive phenotype when grown in nude mice (30, 31). We expressed the reporter genes luciferase and GFP, or DsRed, from lentivirus to follow tumor growth. Although U1242 cells spread invasively in the brain with high mitotic index, similar to human disease, U87 cells form encapsulated tumors (Fig. 2 and Supplementary Fig. S1). We chose to test KU-60019 on U1242 tumors in our initial experiments because these cells recapitulate the pathology of the human disease to some extent. ATM phosphorylates many proteins in response to radiation and DNA damage (32).
Commercially available osmotic pumps to deliver KU-tial systemic toxicity (33, 34). We first explored the use of
directly to the tumor to improve efficacy and reduce poten-
tially bypass the BBB/BTB and deliver drugs
meaningful drug concentrations of KU-60019 within the
tumor, the BBB/BTB need to be bypassed or drugs admin-
istered locally. Both osmotic pumps, as well as clinically
used CED, partially bypass the BBB/ BTB and deliver drugs
directly to the tumor to improve efficacy and reduce poten-
tially systemic toxicity (33, 34). We first explored the use of
commercially available osmotic pumps to deliver KU-
60019 at effective levels to the brain. Preliminary results
with a dye acting as a surrogate for KU-60019 suggested that
efficient spread occurred (Supplementary Fig. S2). When
mice harboring U1242/luc-GFP tumors were treated with
KU-60019 administered from an osmotic pump followed
by 2 Gy of irradiation, we were able to show a complete
elimination of tumor cells on day 20 by BLI 7 days after
radiation (Fig. 4A, top), a finding that was confirmed by
GFP imaging of the extracted brain (Fig. 4A, bottom). This
result suggested that osmotic pumps administered KU-60019
to sufficient levels to radiosensitize U1242 gliomas.
Encouraged by this marked result, we then designed an
experiment to determine the effect of KU-60019 and radi-
ation on the survival of mice. Mice with U1242/luc-GFP
intradural tumors were implanted with osmotic pumps
loaded with KU-60019 7 days after cell implantation,
followed by a single dose of radiation on day 13. Mice treated
with KU-60019 and radiation survived for 109 days, signifi-
cantly longer (P = 0.004 vs. all treatments) than mice
administered KU-60019 alone (35 days), radiation alone (34
days), or after no treatment (27 days; Fig. 4B). However, we
noticed a considerable variation in the survival of the mice
in the KU-60019 and radiation group. Some mice barely
showed a survival benefit, whereas others (e.g., A51 and
A53) showed complete responses and survived for more
than 200 days. Despite initially having tumors, at the time
euthanasia these mice showed no signs of the disease

Among the best characterized targets are H2AX, KAP1, and
53BP1, all linked to processes associated with DNA double-
strand break repair. When mice growing intracranial tumors
were irradiated, we were able to document dose-dependent
increases in γ-H2AX, p-(S824)-KAP1, and 53BP1 repair foci
immediately following radiation (Fig. 3A–C), and in a time
course (Fig. 3D). These results show that invasive human
glioma U1242 cells show evidence of radiation-induced DDR,
permitting the analysis of KU-60019–dependent ATM inhibition in mice.

KU-60019 radiosensitizes orthotopic glioma xenografts and significantly extends the survival of
mice

When KU-60019 is systemically administered either
intraperitoneally or orally, plasma levels only reach the low
micromolar range, which is barely able to radiosensitize
flank tumors (21). The blood–brain barrier (BBB) and
blood–tumor barrier (BTB) represent major obstacles in
the effective treatment of brain tumors (33). To reach
meaningful drug concentrations of KU-60019 within
the tumor, the BBB/BTB need to be bypassed or drugs admin-
istered locally. Both osmotic pumps, as well as clinically
used CED, partially bypass the BBB/ BTB and deliver drugs
directly to the tumor to improve efficacy and reduce poten-
tially systemic toxicity (33, 34). We first explored the use of
commercially available osmotic pumps to deliver KU-
60019 at effective levels to the brain. Preliminary results
with a dye acting as a surrogate for KU-60019 suggested that
efficient spread occurred (Supplementary Fig. S2). When
mice harboring U1242/luc-GFP tumors were treated with
KU-60019 administered from an osmotic pump followed
by 2 Gy of irradiation, we were able to show a complete
elimination of tumor cells on day 20 by BLI 7 days after
radiation (Fig. 4A, top), a finding that was confirmed by
GFP imaging of the extracted brain (Fig. 4A, bottom). This
result suggested that osmotic pumps administer KU-60019
to sufficient levels to radiosensitize U1242 gliomas.
Encouraged by this marked result, we then designed an
experiment to determine the effect of KU-60019 and radi-
ation on the survival of mice. Mice with U1242/luc-GFP
intradural tumors were implanted with osmotic pumps
loaded with KU-60019 7 days after cell implantation,
followed by a single dose of radiation on day 13. Mice treated
with KU-60019 and radiation survived for 109 days, signifi-
cantly longer (P = 0.004 vs. all treatments) than mice
administered KU-60019 alone (35 days), radiation alone (34
days), or after no treatment (27 days; Fig. 4B). However, we
noticed a considerable variation in the survival of the mice
in the KU-60019 and radiation group. Some mice barely
showed a survival benefit, whereas others (e.g., A51 and
A53) showed complete responses and survived for more
than 200 days. Despite initially having tumors, at the time
euthanasia these mice showed no signs of the disease

Figure 4. Radiosensitization of orthotopic U1242/luc-GFP tumors with KU-60019. Athymic female mice were implanted with U1242/luc-GFP cells. Osmotic
pumps (ALZET M2002) were filled with KU-60019 or PBS, connected to a cannula (Brain Infusion Kit 3; ALZET), inserted in the skull at a depth of 3 mm at
the site of cell injection, and the pump placed under the skin on the back of the mouse. The M2002 pump delivers the drug at a rate of 0.5 μL/h over
14 days. A, mice with tumors were imaged by BLI 7 days postcell injection followed by pump implantation with KU-60019 (10 μmol/L; +KU) or not (–KU).
Tumor growth was determined at 13 days by BLI followed by 2 Gy of cranial irradiation to both mice. Seven days later (day 20), mice were imaged by BLI,
euthanized, and the brains removed for GFP imaging using Caliper IVIS-200. Tumor was evident in the brain receiving radiation alone, but not in
the brain receiving KU-60019 and radiation. B, radiosensitization of U1242/luc-GFP tumors with KU-60019 delivered by intratumoral osmotic pump. Cells
were injected followed by implantation of osmotic pumps as in A except that pumps (ALZET M1007D) were inserted 7 days after cell implantation and
radiation (single dose of 5 Gy) was done 7 days (day 14) later. Tumor growth was monitored by BLI. Two mice (A51 and A53), in the KU-60019 and
radiation group that survived for more than 200 days and were apparently healthy when euthanized. Mean survival: no treatment; 27 days, KU-60019; 35
days, KU-60019 + 5 Gy; 109 days, KU-60019 + 5 Gy; 109 days (N = 5). A significant 75-day growth-delay between the KU-60019 and radiation and radiation alone groups was noted (P = 0.00402 vs. all treatments).
We suspected these differences in survival were a result of variable drug delivery throughout the brain because of insufficient ability of this type of pump to apply positive pressure. Therefore, we decided to administer KU-60019 in a manner used clinically, that is, by CED, immediately before irradiation. We also decided to repeat this procedure 3 times in line with clinical practice and possibly achieve a better therapeutic response, whereas using a low dose of radiation to maximize detection of the KU-60019 effect.

To compensate for the relatively small volume that can be infused by CED over a reasonable time, the concentration of KU-60019 was increased to 250 μmol/L. Using these conditions, drug distribution in the mouse brain was determined by liquid chromatography/mass spectrometry (LC/MS) analysis and shown to be concentrated around the

(Supplementary Fig. S3). We suspected these differences in survival were a result of variable drug delivery throughout the brain because of insufficient ability of this type of pump to apply positive pressure. Therefore, we decided to administer KU-60019 in a manner used clinically, that is, by CED, immediately before irradiation. We also decided to repeat this procedure 3 times in line with clinical practice and possibly achieve a better therapeutic response, whereas using a low dose of radiation to maximize detection of the KU-60019 effect.

To compensate for the relatively small volume that can be infused by CED over a reasonable time, the concentration of KU-60019 was increased to 250 μmol/L. Using these conditions, drug distribution in the mouse brain was determined by liquid chromatography/mass spectrometry (LC/MS) analysis and shown to be concentrated around the

( Supplementary Fig. S3). We suspected these differences in survival were a result of variable drug delivery throughout the brain because of insufficient ability of this type of pump to apply positive pressure. Therefore, we decided to administer KU-60019 in a manner used clinically, that is, by CED, immediately before irradiation. We also decided to repeat this procedure 3 times in line with clinical practice and possibly achieve a better therapeutic response, whereas using a low dose of radiation to maximize detection of the KU-60019 effect.

To compensate for the relatively small volume that can be infused by CED over a reasonable time, the concentration of KU-60019 was increased to 250 μmol/L. Using these conditions, drug distribution in the mouse brain was determined by liquid chromatography/mass spectrometry (LC/MS) analysis and shown to be concentrated around the

( Supplementary Fig. S3). We suspected these differences in survival were a result of variable drug delivery throughout the brain because of insufficient ability of this type of pump to apply positive pressure. Therefore, we decided to administer KU-60019 in a manner used clinically, that is, by CED, immediately before irradiation. We also decided to repeat this procedure 3 times in line with clinical practice and possibly achieve a better therapeutic response, whereas using a low dose of radiation to maximize detection of the KU-60019 effect.

To compensate for the relatively small volume that can be infused by CED over a reasonable time, the concentration of KU-60019 was increased to 250 μmol/L. Using these conditions, drug distribution in the mouse brain was determined by liquid chromatography/mass spectrometry (LC/MS) analysis and shown to be concentrated around the

( Supplementary Fig. S3). We suspected these differences in survival were a result of variable drug delivery throughout the brain because of insufficient ability of this type of pump to apply positive pressure. Therefore, we decided to administer KU-60019 in a manner used clinically, that is, by CED, immediately before irradiation. We also decided to repeat this procedure 3 times in line with clinical practice and possibly achieve a better therapeutic response, whereas using a low dose of radiation to maximize detection of the KU-60019 effect.

To compensate for the relatively small volume that can be infused by CED over a reasonable time, the concentration of KU-60019 was increased to 250 μmol/L. Using these conditions, drug distribution in the mouse brain was determined by liquid chromatography/mass spectrometry (LC/MS) analysis and shown to be concentrated around the
Figure 6. Genetically matched human glioma differing in p53 status show a significantly different response to KU-60019. U87/luc-DsRed (p53 wild-type) cells were infected with a mouse retrovirus expressing the p53-281G allele. A, Western blotting for p53 shows the presence of p53-281G in U87-281G cells but not in the parental U87 cells. B, cell-cycle analysis (BrdUrd and 7-AAD flow cytometry) of untreated and irradiated (10 Gy) cells shows that the G1–S checkpoint is abrogated in U87-281G, whereas parental cells have an intact checkpoint. Both cell populations have intact G2–M checkpoints.
infusion site spreading 1 to 2 mm longitudinally (Supplementary Table S1). KU-60019 reached peak concentrations of approximately 5 μmol/L above those needed to inhibit ATM (21). Mice with U1242/luc-GFP intracranial tumors were infused with KU-60019 by CED on day 6, 9, and 12, immediately followed each time with 3 Gy of radiation (Fig. 5A). Mice treated with KU-60019 and radiation survived for 60 days, significantly longer (P = 0.00238 vs. all other treatments) than mice treated with KU-60019 alone (38 days), radiation alone (38 days), or after no treatment (35 days). Increased survival after KU-60019 and radiation was reflected in the reduced impact of tumor growth determined by BLI on day 5, 16, and 30 (Supplementary Fig. S4). To ensure that the levels of drug delivered into the brain were sufficient to block ATM kinase activity, we examined the ability of the drug to inhibit γ-H2AX foci formation (25, 35). We found that KU-60019 was able to inhibit foci formation in both tumor (elongated nuclei) as well as mouse brain (round nuclei with characteristic, large nucleoli; Fig. 5B and C). A similar reduction was seen when p-(S824)-KAP1 foci was examined (Supplementary Fig. S5). These results suggest that CED is able to effectively administer KU-60019 and penetrate diseased brain to radiosensitize the tumor. In addition, normal brain showed a similar response to radiation and KU-60019 in what seemed to be a subpopulation of cells, but presently, we do not know what these cells are or the impact on the brain. Nevertheless, a significant prolongation of survival was seen with KU-60019 and radiation at a radiation dose that produced negligible effects on survival when used as a single agent.

p53-mutant gliomas treated with KU-60019 are more radiosensitive than their isogenic, p53 wild-type counterparts

To explore the ability of KU-60019 to radiosensitize other human gliomas, we turned to U87 cells, which have been used extensively in the past in similar studies. Furthermore, U87 cells express wild-type p53 making it possible to manipulate p53 status and show possible effects on radiosensitization and the response to KU-60019. To generate U87/luc-DsRed cells with mutant p53, we infected cells with a retrovirus expressing the p53-281G allele (36), and with the KU-60019 and radiation combination survived longer than radiation alone mice (P = 0.0448), there was no difference in survival between this group and the KU-60019 alone group. There was a statistical difference in survival between KU-60019 alone and the no treatment groups (P = 0.00019). Thus, U87 glioma is relatively refractory to KU-60019 radiosensitization. On the other hand, mice with U87-281G tumors (Fig. 6F, top), treated with the KU-60019 and radiation combination survived more than 160 days, significantly longer (P = 0.00011 vs. all other treatments) than mice treated with KU-60019 alone (51 days), radiation alone (44 days), or after no treatment (42 days). Similar to the results with mice harboring parental U87 tumors, mice treated with KU-60019 alone showed a trend toward longer survival but this difference was not significant (P = 0.13). Thus, genetically matched p53-mutant U87 tumors dramatically responded to KU-60019 radiosensitization resulting in a subset of mice in this group apparently cured of disease. In addition, there was a trend of increased survival of mice treated with KU-60019 alone in both the p53 wild-type and 281G-mutant sets lending...
support to the idea that inhibiting ATM might reduce tumor dispersal in between radiation fractions (21).

Before we had verified the p53 status of the U1242 cells as having the R175H mutation, in agreement with previous reports (38, 39), we had already infected these cells with the retrovirus expressing the p53-281G allele and initiated a survival experiment. In support of the data obtained with the U87 p53-matched experiment, we noticed a significant improvement in the response to the kinase inhibitor, KU-60019 and radiation with U1242/p53-281G tumors compared with parental U1242 tumors (Supplementary Fig. S7). Mice with U1242/p53-281G tumors treated with KU-60019 followed by radiation, survived for 145 days, significantly longer ($P = 0.0004$) than mice treated with KU-60019 alone (66 days), radiation alone (58 days), or no treatment (52 days). Also, mice with U1242/p53-281G-mutant tumors responded significantly better to treatment than mice with parental U1242 tumors across all treatments ($P = 0.0004$), corroborating the results with the U87 set that glioma with a p53 mutation is more sensitive to KU-60019 radiosensitization. The mechanism underlying the enhanced response as a result of manipulating p53 status in the U1242 cells is not known but currently under investigation. It is possible that 281G and 175H cooperate in some fashion to make these cells more sensitive to radiosensitization by KU-60019 (40), or, alternatively, 175H might gain some function when 281G is also expressed resulting in a more responsive phenotype.

Discussion

Inhibiting ATM for cancer therapy has been a long-sought goal for radiobiologists and oncologists alike (14). With the advent of highly specific inhibitors for the ATM kinase, this has recently become a reality (18–20). We have shown herein that the ATM kinase inhibitor, KU-60019, was able to radiosensitize gliomas grown orthotopically in mice. Radiosensitization was most striking in U87 gliomas expressing mutant p53, where a large proportion of the mice seemed to have been cured of disease.

There are no known unique ATM phosphorylation sites (32). However, H2AX and KAP1 are considered more specific targets for the ATM kinase at early times after radiation, whereas the related DNA-PK and ATR kinases serve as complementary backups for ATM at later times (20, 41–43). We were able to validate ATM inhibition by KU-60019 in vivo by showing reduced γ-H2AX, as well as p-(S824)-KAP1, foci formation immediately following irradiation in both the tumor and mouse brain. These results suggest that KU-60019 is able to inhibit the ATM kinase in tissue regardless of whether it is cancerous or not. Because increased survival correlated well with the ability of KU-60019 to suppress foci formation, this suggests that interfering with ATM signaling caused the reduction in tumor growth and prolonged the survival of mice.

We have shown in this study that glioma with mutant p53 is much more sensitive to KU-60019–dependent radiosensitization. This result was not unexpected as several recent studies have shown that human lymphomas with double mutations in p53 and ATM, or Chk2, were much more sensitive to chemotherapy than tumors with a single mutation (44–46). Several excellent reviews have discussed therapeutic strategies based on the DDR synthetic lethality principle (47, 48). In addition, caffeine, a broad-spectrum phosphatidyl inositol 3’ kinase-related kinase inhibitor, was shown to radiosensitize p53 null but not matched p53 wild-type cells in vitro (49, 50). The results from our study underscore these previous findings and extend this concept by showing enhanced radiosensitization of p53-mutant glioma with an ATM kinase inhibitor in vivo. Importantly, tumors with normal p53 were found to be protected against chemotherapy (44). Thus, one would assume that normal tissues and cells would be protected as well. It was recently shown that under conditions in which the cell-cycle kinase Cdk1 was inhibited or depleted, normal, nontransformed cells were protected against DNA-damaging drugs while tumor cells were efficiently killed (51). We are also encouraged by the result that p53 null mouse glioma stem cells were radiosensitized by KU-60019, a result in agreement with a previous study (29). Therefore, targeting the ATM kinase with a small-molecule inhibitor in p53-mutant glioma would be very attractive as it is expected that the glioma would be sensitive to radiation, whereas normal tissue would be protected or less affected.

Even though U1242 tumors harbor the p53 R175H allele, they were not as sensitive to KU-60019 and radiation as the U87/p53-281G tumors based on survival. We speculate that this is due to the ability of U1242 tumors to spread throughout the brain (see Supplementary Fig. S1), and perhaps evade the drug. On the other hand, U87 tumors are encapsulated and more contained, thus providing a more accessible, physical target for KU-60019. Therefore, it is likely that mice harboring U1242 tumors die from tumor dispersal throughout the brain parenchyma, whereas mice with U87 tumors die from increased intracranial pressure produced by the tumor. The differential response to KU-60019 and enhanced radiosensitization seen in vivo with p53-mutant gliomas is not reflected in vitro as both U87 (wild-type) and U1242 (p53 mutant) are similarly radiosensitized (see Fig. 1). In sharp contrast, the p53 effect can be seen clearly in vitro when isogenic cells differing only in p53 status are compared as we did with the U87 cells (see Fig. 6C–E). We attribute differences in results between experiments using osmotic pump and CED a reflection of different experimental conditions and duration of drug exposure. Ongoing studies using panels of human and mouse gliomas and primary glioma stem cells with varying p53 status are exploring the use of higher doses of radiation to maximize survival, and identifying potential side effects of KU-60019 on normal brain. Whether KU-60019 radiosensitization seen at higher doses of radiation in vitro would also be observed in vivo is currently not known. However, at higher radiation doses one would not be able to take full advantage of the radiosensitizer and spare normal tissue as higher radiation doses will likely damage the brain despite having normal p53. Furthermore, whether...
treatment with KU-60019 alone provides a survival benefit that is currently under investigation.

Local drug delivery increases the therapeutic effect and at the same time reduces general toxicity to treated subjects. CED is becoming a more frequent experimental treatment option in the management of brain tumours but adds complexity and cost to the procedure. In addition, technical difficulties associated with cannula placement verification and the prevention of drug backflow are issues that still need to be resolved (33). Although the effect of KU-60019 radiosensitization on tumors is clear, the effect on mouse brain is not known. This issue has not been a primary concern when patients survive for just a little more than a year, at best. We have not observed gross abnormalities on normal mouse brain after treatment with KU-60019 and radiation. Further studies on the response of normal tissue to KU-60019, and the brain in particular, with and without radiation, are therefore needed as prolonging survival of subjects would likely expose any detrimental late effects on brain function and cognition due to treatment. However, it is important to point out that all treatments induce damage in normal tissues, a side effect of cancer therapy and fact that needs to be balanced against therapeutic gain and quality of life. Delivery of an ATM inhibitor locally by CED should in part alleviate such concern.

Altogether, our results suggest that ATM kinase inhibition may be an effective adjuvant therapy for patients with mutant p53 brain cancers. Because a third of all GBM cases have p53 mutations, this population of patients might be a particularly attractive target group.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


Authors’ Contributions

Conception and design: L. Biddlestone-Thorpe, M. Sajjad, M.J. O’Connor, K. Valerie


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Sajjad, E. Rosenberg, M. Tokarz, N.D. Mukhopadhyay

Study supervision: K. Valerie

Acknowledgments

The authors thank Khalid Shah (Harvard University, Cambridge, MA) for virus reagent and Michael Kastan (Duke University, Durham, NC) for helpful discussion.

Grant Support

This work was supported by NIH Grants RO1NS064593 and R21CA156993 (to K. Valerie). L. Biddlestone-Thorpe was supported by T32CA113277. S.E. Golding was supported by American Brain Tumor Association and T32CA085159. A.F. Wagner by T32CA085159, and J.M. Beckta by F30CA171893. Shared Resources used in this project were supported by VCU, the Massey Cancer Center (P30CA016059), and the Department of Neurobiology & Anatomy Microscopy Facility (supported in part by P30NS047463).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 2, 2012; revised April 1, 2013; accepted April 12, 2013; published OnlineFirst April 25, 2013.
Biddlestone-Thorpe et al.


ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation

Laura Biddlestone-Thorpe, Muhammad Sajjad, Elizabeth Rosenberg, et al.


**Updated version**
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-3408

**Supplementary Material**
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/04/30/1078-0432.CCR-12-3408.DC1

**Cited articles**
This article cites 50 articles, 23 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/19/12/3189.full#ref-list-1

**Citing articles**
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/19/12/3189.full#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.